-
-
-
-
-
-
-
INmune Bio reports 2025 financial results, plans regulatory filings
-
-
-
-
-
-
-
INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c
-
-
-
-
-
-
-
Increasing unusual call option volume: CFG INMB KBE TRIP TAP JNPR FEZ VNET PUBM JOBY NEXT FLNC
-
-
-
-
-
-
-
INmune Bio (INMB): XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
-
-
-
-
-
-
-
INmune Bio Inc. (INMB) PT Raised to $23 at Raymond James
-
-
-
-
-
-
-
INmune Bio (INMB) Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
-
-
-
-
-
-
-
INmune Bio, Inc. (INMB) Tops Q2 EPS by 13c
-
435,358 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

